Unstable angina

Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

Retrieved on: 
Monday, November 11, 2019
Acute pain, Medicine, Medical specialties, Clinical medicine, Aging-associated diseases, RTT, Medical emergencies, Unstable angina, Angina, Amgen, Myocardial infarction, Revascularization

THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia, Nov. 16-18.

Key Points: 
  • THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia, Nov. 16-18.
  • "In addition, we look forward to presenting data that showcases the potential of omecamtiv mecarbil for the treatment of heart failure.
  • The primary endpoint is the time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
  • A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data.

FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

Retrieved on: 
Saturday, April 27, 2019
Circulatory system, RTT, Cardiovascular system, Cardiology, Angina, Coronary artery disease, Unstable angina, Cardiovascular disease, Heart, Percutaneous coronary intervention

Adults who experience a heart attack or stroke have an approximately one in three chance to have another CV event.

Key Points: 
  • Adults who experience a heart attack or stroke have an approximately one in three chance to have another CV event.
  • The primary endpoint included time to first heart attack, stroke, death from coronary heart disease (CHD), or unstable angina requiring hospitalization (HR 0.85; 95% CI, 0.78 to 0.93; p=0.0003).
  • A 27% reduced risk of stroke, 14% reduced risk of non-fatal heart attack and 39% reduced risk of unstable angina requiring hospitalization.
  • In the U.S., Praluent is approved to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established CV disease.

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

Retrieved on: 
Wednesday, March 6, 2019
Medical specialties, Cardiology, Lipids, Medicine, Acute pain, RTT, Aging-associated diseases, Lipoproteins, Low-density lipoprotein, Unstable angina, Angina, Myocardial infarction

This program of clinical studies investigates the impact of Repatha on LDL-C and CVD across multiple populations.

Key Points: 
  • This program of clinical studies investigates the impact of Repatha on LDL-C and CVD across multiple populations.
  • Eligible patients with FH were given subcutaneous evolocumab 420 mg monthly or 420 mg every 2 weeks if on lipoprotein apheresis.
  • The primary endpoint is the time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.
  • A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data.

Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease

Retrieved on: 
Saturday, October 27, 2018
RTT, Medicine, Acute pain, Aging-associated diseases, Medical emergencies, Clinical medicine, Anatomy, Cardiovascular disease, Chronic kidney disease, Unstable angina, Angina, Amgen

THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function.

Key Points: 
  • THOUSAND OAKS, Calif., Oct. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function.
  • Adverse events were similar across patients regardless of CKD stage and consistent with the Repatha known safety profile.
  • "Patients with chronic kidney disease are considered a high-risk population due to increased rates of cardiovascular events associated with impaired kidney function," said Robert P.
  • The primary endpoint is the time to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

Alterations in Copper Homeostasis in Ischemic Heart Disease

Retrieved on: 
Wednesday, May 30, 2018
Circulatory system, Medicine, Cardiology, Aging-associated diseases, Heart diseases, RTT, Medical emergencies, Acute pain, Ischemia, Coronary artery disease, Unstable angina, Ischemic cardiomyopathy

Myocardial ischemia occurs when blood flow to the heart is reduced and the heart muscle (myocardium) does not receive enough oxygen to function normally.

Key Points: 
  • Myocardial ischemia occurs when blood flow to the heart is reduced and the heart muscle (myocardium) does not receive enough oxygen to function normally.
  • It has been known for many years that patients with myocardial ischemia have elevated levels of copper in the blood.
  • Reduced copper levels in the ischemic heart suggest that ischemic injury may cause the heart to release copper into the blood.
  • As important, we found that a copper chaperone is involved in the release of myocardial copper.

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

Retrieved on: 
Wednesday, May 16, 2018
RTT, Circulatory system, Medicine, Angiology, Coronary artery disease, Angina, Unstable angina, Atherosclerosis, Myocardial infarction, Cardiovascular disease, Clinical endpoint, Stroke

"With its proven ability to prevent heart attacks and strokes, Repatha offers hope for one of the greatest health challenges we face today.

Key Points: 
  • "With its proven ability to prevent heart attacks and strokes, Repatha offers hope for one of the greatest health challenges we face today.
  • "With far too many patients at risk of recurrent cardiovascular events, we are pleased that the European Commission has approved Repatha to prevent heart attacks and strokes in adults with established atherosclerotic cardiovascular disease.
  • The hard MACE composite endpoint was the time to cardiovascular death, myocardial infarction or stroke (key secondary endpoint).
  • The extended MACE composite endpoint was the time to cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (primary endpoint).